ON THE ROLE OF RANDOMIZED CLINICAL TRIALS IN MEDICINE

被引:1
作者
Christensen, Michael C. [1 ]
Moskowitz, Alan [1 ]
Talati, Ardesheer [1 ]
Nelson, Richard R. [2 ]
Rosenberg, Nathan [3 ]
Gelijns, Annetine C. [1 ]
机构
[1] Columbia Univ, Int Ctr Hlth Outcomes & Innovat Res, New York, NY 10027 USA
[2] Columbia Univ, Sch Int & Publ Affairs, New York, NY USA
[3] Stanford Univ, Dept Econ, New York, NY USA
关键词
Randomized clinical trial; Education; Drugs; Devices; Clinical practice;
D O I
10.1080/10438590600982426
中图分类号
F [经济];
学科分类号
02 ;
摘要
The placebo-controlled, double-blind, randomized clinical trial (RCT) holds unique advantages for evaluating medical technologies, and figures prominently in clinical drug investigations. However, medicine, like other social sectors, has experienced a movement toward evidence-based practice and policy decision-making that involves the evaluation of complex non-pharmacological interventions that frequently challenge the use of the RCT. Even with pharmaceuticals used in clinical practice, the application of RCTs has its limitations and challenges. This paper argues that both the modality of therapy (drugs, devices, and procedures) and the stage of technological evolution are important determinants of an optimal evaluative design. The practicality of conducting an RCT is inversely proportional to the complexity of the healthcare intervention. Iterative modifications of medical devices, provider-specific practices, and an evolving clinical knowledge-base are just some of the problems plaguing technology assessments. Lessons learned on the role of randomized versus observational study designs may prove valuable for other social sectors.
引用
收藏
页码:357 / 370
页数:14
相关论文
共 29 条
  • [1] A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITH ZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    ABRAMS, DI
    GOLDMAN, AI
    LAUNER, C
    KORVICK, JA
    NEATON, JD
    CRANE, LR
    GRODESKY, M
    WAKEFIELD, S
    MUTH, K
    KORNEGAY, S
    COHN, DL
    HARRIS, A
    LUSKINHAWK, R
    MARKOWITZ, N
    SAMPSON, JH
    THOMPSON, M
    DEYTON, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10) : 657 - 662
  • [2] THYROID CARCINOMA AFTER RADIATION THERAPY FOR ADOLESCENT ACNE VULGARIS
    ALBRIGHT, EC
    ALLDAY, RW
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1967, 199 (04): : 280 - &
  • [3] [Anonymous], 1986, LANCET, V2, P57
  • [4] The political economy of FDA drug review: Processing, politics, and lessons for policy
    Carpenter, DP
    [J]. HEALTH AFFAIRS, 2004, 23 (01) : 52 - 63
  • [5] Centers for Disease Control and Prevention (CDC), 2005, DES HIST
  • [6] Controlled trials: the 1948 watershed
    Doll, R
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7167): : 1217 - 1220
  • [7] FDA, 2004, INN STAGN CHALL OPP
  • [8] Flack M., 2005, ADV PATIENT SAFETY, V3, P223
  • [9] Food and Drug Administration (FDA), 2003, REP NAT IMPR PUBL HL
  • [10] NIFEDIPINE - DOSE-RELATED INCREASE IN MORTALITY IN PATIENTS WITH CORONARY HEART-DISEASE
    FURBERG, CD
    PSATY, BM
    MEYER, JV
    [J]. CIRCULATION, 1995, 92 (05) : 1326 - 1331